“…One compound, IND-2, selectively inhibited the growth of colon cancer cells (HCT-116, S1-MI-80, HT-29, HCT-15, LS-180, LS-174, and Lovo) at submicromolar concentrations. Although the other IND derivatives did not display significant efficacy as anticancer compounds [15], most of the 2-methylpyrimido [1″,2″: 1,5]pyrazolo [3,4-b]quinolines incorporated structural features deemed significant for reversing MDR, such as a polycyclic aromatic ring, protonable nitrogen, H-bond donors/acceptors and lipophilicity [16]. The presence of key structural features required for MDR reversal activity, with the lack of cytotoxicity (>50 μM) in Colon carcinoma cell lines, HCT-116, HCT-15, HT-29, Lovo, LS-180, LS-174, S1 (a clone of LS174T cells), and S1-M1-80 (resistant); prostatic cancer cell lines, DU-145 and PC-3; breast carcinoma cells, MDA-MB-231 and MCF-7; ovarian cancer cells, ov2008 and A2780; canine kidney MDCK cells; mouse fibroblast NIH/3T3 cells; human liver cells HepG2 [15], suggests that the 2-methylpyrimido [1″,2″: 1,5]pyrazolo [3,4-b]quinoline derivatives may have efficacy as MDR reversal compounds that could enhance the anticancer efficacy of traditional chemotherapeutics by interacting with ABCG2 transporters.…”